Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment

Journal of Neural Transmission

Volumn 119, Issue 7, 2012, Pages 821-831

  Kruczyk, Marcin ^a,b,c   Zetterberg, Henrik ^d,e   Hansson, Oskar ^f,g   Rolstad, Sindre ^d   Minthon, Lennart ^f,g   Wallin, Anders ^d   Blennow, Kaj ^d   Komorowski, Jan ^b,c   Andersson, Mats Gunnar ^h  

^a Postgraduate School for Molecular Medicine   (Poland)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF WARSAW   (Poland)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Decision support; Monte Carlo feature selection; Rosetta; Rough sets

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; TAU PROTEIN;

ACCURACY; AGED; ALGORITHM; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTE CARLO METHOD; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; MONTE CARLO METHOD; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; TAU PROTEINS;

EID: 84863465731     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0812-0     Document Type: Article

References (34)

1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. American Psychiatric Association, Arlington
2. Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, Nordberg A (2001) Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitiv eimpairment. Neuroreport 12:851-855
3. Blennow K, Zetterberg H (2006) Pinpointing plaques with PIB. Nat Med 12:753-754
4. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403
5. Borroni B, Anchisi D, Paghera B, Vicini B, Kerrouche N, Garibotto V, Terzi A, Vignolo LA, Di Luca M, Giubbini R, Padovani A, Perani D (2006) Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol Aging 27:24-31
6. Breiman L (2001) Random forests. Mach Learn 45:5-32
7. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ (2009) Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30:682-690
8. Chetelat G, Eustache F, Viader F, De La Sayette V, Pélerin A, Mézenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B (2005) FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11:14-25
9. Draminski M, Rada-Iglesias A, Enroth S, Wadelius C, Koronacki J, Komorowski J (2009) Monte Carlo feature selection for supervised classification. Bioinformatics 25:1165-1172
10. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B (2006) Mild cognitive impairment. Lancet 367:1262-1270
11. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K (2004) Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9:705-710
12. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228-234
13. Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S (2007) Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 30:165-173
14. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010) Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis 21:1119-1128
15. Herukka SK, Hallikainen M, Soininen H, PirttiläT (2005) CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 6:1294-1297
16. Hvidsten TR, Komorowski J (2007) Rough sets in bioinformatics. In: Marek VW, Orlowska E, Slowinski R, Ziarko W (eds) Transactions on rough sets VII. LNCS, vol 4400. Springer, Heidelberg, pp 225-243
17. John GH, Langley P (1995) Estimating continuous distributions in Bayesian classifiers. In: Proceedings of the eleventh conference on uncertainty in artificial intelligence, San Mateo, pp 338-345
18. Kierczak MDM, Koronacki J, Komorowski J (2010) Computational analysis of molecular interaction networks underlying change of HIV-1 resistance to selected reverse transcriptase inhibitors. Bioinform Biol Insights 4:137-146
19. Le Cessie S, van Houwelingen JC (1992) Ridge estimators in logistic regression. Appl Stat 41:191-201
20. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, Petereit HF, Tumani H, Gerritzen A, Oschmann P, Schröder J, Schönknecht P, Zimmermann K, Hampel H, Bürger K, Otto M, Haustein S, Herzog K, Dannenberg R, Wurster U, Bibl M, Maler JM, Reubach U, Kornhuber J, Wiltfang J (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409:1-4
21. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, PirttiläT, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385-393
22. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, LladóA, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Para skevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7:386-395
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
24. Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, Li Y, Boppana M, de Leon MJ (2005) Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64:1860-1867
25. Nguyen HS (2006) Approximate Boolean reasoning: foundations and applications in data mining. LNCS 4100:334-506
26. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A (2005) The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 76:1485-1490
27. Pawlak Z (1982) Rough sets. Int J Parallel Program 11:341-356
28. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183-194
29. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and betaamyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59:1729-1734
30. Shaw LM, Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65:403-413
31. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 46:235-240
32. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8:619-627
33. Zetterberg H, Wahlund LO, Blennow K (2003) Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352:67-69
34. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A (2007) Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 12:255-260